MUMBAI, India and NEW YORK , May 23, 2024 /CNW/ - - Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associates referred as "Sun Pharma") and Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") today announced that the merger agreement between Taro and Sun Pharma was approved by the affirmative vote of Taro... Read More

HAWTHORNE, N.Y. / May 20, 2024 / Business Wire / Taro Pharmaceutical Industries Ltd . (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and year ended March 31, 2024. Quarter ended March 31, 2024 Highlights ─ compared to March 31, 2023 Net sales of $164.9 million increased $18.4 million, or 12.5%, principally due to new launches and gross-to-net (“GTN”) adjustments. Excluding... Read More

HAWTHORNE, N.Y. / May 15, 2024 / Business Wire / Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for year ended March 31, 2024, after the close of market on Monday, May 20, 2024. The release will be accessible on Taro’s website at www.taro.com . About Taro Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to... Read More

NEW YORK / May 08, 2024 / Business Wire / Taro Pharmaceutical Industries Ltd . (NYSE: TARO) (“Taro” or the “Company”) today announced that leading independent proxy advisory firms Institutional Shareholder Services (“ISS”) and Glass Lewis & Co. (“Glass Lewis”) have both recommended that Taro shareholders vote “FOR” the pending Merger transaction with Sun Pharmaceutical Industries Ltd. (“Sun Pharma”) at the upcoming May 22,... Read More

NEW YORK / Apr 15, 2024 / Business Wire / Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today announced that it has called an extraordinary general meeting of its shareholders (the “Extraordinary General Meeting”), to be held on May 22, 2024, at 10:00 a.m., Israel time, and a class meeting (the “Ordinary Class Meeting” and together with the Extraordinary General Meeting, the “Meetings”) of the... Read More

NEW YORK , Jan. 30, 2024 /PRNewswire/ -- Krensavage Asset Management today sent the following message to a special committee evaluating Sun Pharmaceutical Industries Ltd.'s bid for Taro Pharmaceutical Industries Ltd. Krensavage Asset Management LLC 610 Fifth Avenue Suite 301 New York, NY 10020 info@krensavage.com Taro Special Committee Linda Benshoshan linda@lindabs.co.il Dear Linda, As the largest minority shareholder 1 of... Read More

HAWTHORNE, N.Y. / Jan 25, 2024 / Business Wire / Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and nine months ended December 31, 2023. Quarter ended December 31, 2023 Highlights ─ compared to December 31, 2022 Net sales of $157.1 million increased $17.9 million or 12.9% principally due to new launches and gross-to-net (“GTN”)... Read More

HAWTHORNE, N.Y. / Jan 19, 2024 / Business Wire / Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the third quarter ended December 31, 2023, after the close of market on Thursday, January 25, 2024. The release will be accessible on Taro’s website at www.taro.com . About Taro Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical... Read More

Agreed Price of US$43.00 per Share to Deliver 48% Premium to Unaffected Price on May 25, 2023 MUMBAI, India and NEW YORK , Jan. 17, 2024 /CNW/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associates referred as "Sun Pharma") and Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") today announced that... Read More

HAWTHORNE, N.Y. / Oct 26, 2023 / Business Wire / Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and six months ended September 30, 2023. Quarter ended September 30, 2023 Highlights ─ compared to September 30, 2022 Net sales of $148.2 million increased, in part, due to a one-time gross-to-net (“GTN”) adjustment. Excluding the impact of the... Read More

HAWTHORNE, N.Y. / Oct 19, 2023 / Business Wire / Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the second quarter ended September 30, 2023, after the close of market on Thursday, October 26, 2023. The release will be accessible on Taro’s website at www.taro.com . About Taro Taro Pharmaceutical Industries Ltd. is a multinational, science-based... Read More

HAWTHORNE, N.Y. / Jul 26, 2023 / Business Wire / Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter ended June 30, 2023. Quarter ended June 30, 2023 Highlights ─ compared to June 30, 2022 Net sales increased $2.2 million, or 1.4%, to $158.9 million. Gross profit of $64.1 million (40.3% of net sales) compared to $81.6 million (52.1% of net... Read More

HAWTHORNE, N.Y. / Jul 19, 2023 / Business Wire / Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the first quarter ended June 30, 2023, after the close of market on Wednesday, July 26, 2023. The release will be accessible on Taro’s website at www.taro.com . About Taro Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical... Read More

NEW YORK , July 19, 2023 /PRNewswire/ -- As the largest minority shareholder 1 of Taro Pharmaceutical Industries Ltd. (NYSE: TARO), Krensavage Asset Management LLC opposes Sun Pharmaceutical Industries Ltd.'s paltry bid to take Taro private. Sun, a 78.5% Taro shareholder, on May 26 offered to acquire the rest of Taro for $38 a share, valuing the company at $1.4 billion . Sun's inadequate offer amounts to a 17% discount to... Read More

HAWTHORNE, N.Y. / Jun 30, 2023 / Business Wire / Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro”) announced that its Annual Report on Form 20-F for the fiscal year ended March 31, 2023, filed with the Securities and Exchange Commission (the “SEC”), is available within the Investor Relations section of Taro’s website at www.taro.com . Hard copies of the report may be ordered free of charge by sending requests to:... Read More

HAWTHORNE, N.Y. / May 23, 2023 / Business Wire / Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and year ended March 31, 2023. Quarter ended March 31, 2023* Highlights ─ compared to March 31, 2022 Net sales of $146.6 million increased $3.3 million, or 2.3%. Gross profit of $75.7 million (51.6% of net sales) compared to $77.3 million (54.0%... Read More

HAWTHORNE, N.Y. / May 18, 2023 / Business Wire / Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the year ended March 31, 2023, after the close of market on Tuesday, May 23, 2023. The release will be accessible on Taro’s website at www.taro.com . About Taro Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company,... Read More

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the third quarter ended December 31, 2022, after the close of market on Tuesday, January 24, 2023. The release will be accessible on Taro’s website at www.taro.com . About Taro Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its... Read More